Search results for "CyclinE"

showing 10 items of 194 documents

Influence of polymorphisms in anthracyclines metabolism genes in the standard induction chemotherapy of acute myeloid leukemia

2021

Objectives Genetic variability in anthracycline metabolism could modify the response and safety of acute myeloid leukemia (AML) induction. Methods Polymorphisms in genes that encodes enzymes of anthracyclines metabolic pathway (CBR3: rs1056892, rs8133052, NQO1: rs1800566, NQO2: rs1143684, NOS3: rs1799983, rs2070744) were evaluated in 225 adult de novo AML patients. Results The variant CBR3 rs8133052 was associated with lower hepatotoxicity (P = 0.028). Wild-type genotype of NQO2 rs1143684 was related to higher complete remission (P = 0.014), and the variant allele with greater gastrointestinal toxicity (P = 0.024). However, the variant genotype of NQO1 rs1800566 was associated with mucositi…

Adult0301 basic medicineAnthracycline030226 pharmacology & pharmacyNephrotoxicity03 medical and health sciences0302 clinical medicineGenotypeGeneticsmedicineMucositisHumansIdarubicinAnthracyclinesGenetic variabilityGeneral Pharmacology Toxicology and PharmaceuticsMolecular BiologyAllelesGenetics (clinical)Polymorphism Geneticbusiness.industryInduction chemotherapyMyeloid leukemiaInduction Chemotherapymedicine.diseaseLeukemia Myeloid Acute030104 developmental biologyCancer researchMolecular Medicinebusinessmedicine.drugPharmacogenetics and Genomics
researchProduct

Impact of combinations of single-nucleotide polymorphisms of anthracycline transporter genes upon the efficacy and toxicity of induction chemotherapy…

2020

Anthracycline uptake could be affected by influx and efflux transporters in acute myeloid leukemia (AML). Combinations of single-nucleotide polymorphisms (SNPs) of wild-type genotype of influx transporters (SLC22A16, SLCO1B1) and homozygous variant genotypes of ABC polymorphisms (ABCB1, ABCC1, ABCC2, ABCG2) were evaluated in 225 adult de novo AML patients. No differences in complete remission were reported, but higher induction death was observed with combinations of SLCO1B1 rs4149056 and ABCB1 (triple variant haplotype, rs1128503), previously associated with ABCB1 and SLCO1B1 SNPs. Several combinations of SLCO1B1 and SLC22A16 with ABCB1 SNPs were associated with higher toxicities, includin…

AdultCancer ResearchGenotypeAnthracyclineSingle-nucleotide polymorphismPolymorphism Single Nucleotide03 medical and health sciences0302 clinical medicineMucositisHumansMedicineIdarubicinAnthracyclinesProspective StudiesbiologyLiver-Specific Organic Anion Transporter 1business.industryHaplotypeInduction chemotherapyMyeloid leukemiaInduction ChemotherapyHematologymedicine.diseaseMultidrug Resistance-Associated Protein 2Leukemia Myeloid AcuteOncology030220 oncology & carcinogenesisbiology.proteinCancer researchATP-Binding Cassette TransportersbusinessSLCO1B1030215 immunologymedicine.drugLeukemia & Lymphoma
researchProduct

A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as …

2005

The sequential doxorubicin → CMF (CMF = cyclophosphamide, methotrexate, fluorouracil) regimen has never been compared to CMF in a randomised trial. The role of adding goserelin and tamoxifen after chemotherapy is unclear. In all, 466 premenopausal node-positive patients were randomised to: (a) CMF × 6 cycles (CMF); (b) doxorubicin × 4 cycles followed by CMF × 6 cycles (A → CMF); (c) CMF × 6 cycles followed by goserelin plus tamoxifen × 2 years (CMF → GT); and (d) doxorubicin × 4 cycles followed by CMF × 6 cycles followed by goserelin plus tamoxifen × 2 years (A → CMF → GT). The study used a 2 × 2 factorial experimental design to assess: (1) the effect of the chemotherapy regimens (CMF vs A …

AdultCancer Researchmedicine.medical_specialtyCyclophosphamidemedicine.medical_treatmentUrologyBreast NeoplasmsDisease-Free SurvivalDrug Administration Schedulebreast cancerchemoendocrine treatmentAntineoplastic Combined Chemotherapy ProtocolsClinical StudiesmedicineAdjuvant therapyHumansDoxorubicinCyclophosphamideanthracyclinesGynecologyChemotherapypremenopausalbusiness.industryGoserelinadjuvant therapyMiddle AgedCombined Modality TherapyTamoxifenRegimenMethotrexateOncologyChemotherapy AdjuvantDoxorubicinFluorouracilLymphatic MetastasisGoserelinFemaleFluorouracilbusinessTamoxifenFollow-Up Studiesmedicine.drugBritish Journal of Cancer
researchProduct

Multicenter phase II study of oral idarubicin in treated and untreated patients with B-chronic lymphocytic leukemia.

2000

Idarubicin is the first anthracycline that can be administered orally facilitating antineoplastic chemotherapy at an improved quality of life. In different studies idarubicin has proved clinical effectiveness in patients with advanced low grade non Hodgkin's lymphoma. We performed a phase II study in 19 patients with untreated and pretreated B-CLL of Binet stage A-C. Idarubucin was administered orally at a dose of 15 mg/m2 over 3 days every 4 weeks. Of 19 evaluable patients (m:f, 16:3, median age 64 years, range 41-80 years) 7 were previously untreated while 12 patients had received prior therapy with fludarabine, chlorambucil or similar non-anthracycline containing regimens. 12 pts had Bin…

AdultMaleCancer Researchmedicine.medical_specialtyAnthracyclineNauseaPhases of clinical researchAdministration OralGastroenterology03 medical and health sciences0302 clinical medicineInternal medicinemedicineIdarubicinHumans030304 developmental biologyAged0303 health sciencesAntibiotics AntineoplasticChlorambucilbusiness.industryHematologyMiddle Agedmedicine.diseaseLeukemia Lymphocytic Chronic B-Cell3. Good healthSurgeryFludarabineOncology030220 oncology & carcinogenesisVomitingFemalemedicine.symptombusinessIdarubicinProgressive diseasemedicine.drugLeukemialymphoma
researchProduct

Body Mass Index as a Risk Factor for Toxicities in Patients with Advanced Soft-Tissue Sarcoma Treated with Trabectedin

2017

<b><i>Objectives:</i></b> Low body mass index (BMI) and/or low lean body mass have been shown to be risk factors for chemotherapy-related toxicities in a number of different cancers. However, no data are available regarding the role of BMI as a risk factor for developing toxicities related to the novel anticancer agent, trabectedin, in patients with soft-tissue sarcoma (STS). We evaluated the role of BMI as a risk factor for trabectedin-related toxicity in patients with STS. <b><i>Methods:</i></b> Data from 51 patients with metastatic/advanced STS treated with trabectedin after progression on ≥1 anthracycline ± ifosfamide regimen were retrospe…

AdultMaleOncologySarcopeniaCancer Researchmedicine.medical_specialtyNeutropeniaDioxolesNeutropeniaBody Mass Index03 medical and health sciences0302 clinical medicineThinnessRisk FactorsTetrahydroisoquinolinesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAnthracyclinesIfosfamide030212 general & internal medicineRisk factorAntineoplastic Agents AlkylatingTrabectedinAgedRetrospective StudiesAged 80 and overIfosfamideToxicitybusiness.industrySoft tissue sarcomanutritional and metabolic diseasesSarcomaGeneral MedicineMiddle Agedmedicine.diseaseOncology030220 oncology & carcinogenesisSoft-tissue sarcomaFemaleUnderweightmedicine.symptombusinessBody mass indexFebrile neutropeniaTrabectedinmedicine.drugOncology
researchProduct

Influence of ABCB1 polymorphisms upon the effectiveness of standard treatment for acute myeloid leukemia: A systematic review and meta-analysis of ob…

2015

The ABCB1 gene encodes for P-glycoprotein (P-gp), an efflux pump for a variety of xenobiotics. The role of ABCB1 polymorphisms in acute myeloid leukemia (AML) outcomes of standard chemotherapy (cytarabine plus anthracyclines) remains controversial. A systematic search was made of studies evaluating the association between ABCB1 polymorphisms 1236C>T, 2677G>T/A and 3435C>T and effectiveness variables. We found seven cohort studies (1241 patients) showing a significantly higher overall survival (OS) among carriers of the variant allele of 1236C>T at year 4 (odds ratio (OR): 1.47, 95% confidence interval (CI): 1.07-2.01), 2677G>T/A at years 4-5 (OR: 1.37, 95% CI: 1.01-1.86) and 3435C>T at year…

AdultMaleOncologymedicine.medical_specialtyATP Binding Cassette Transporter Subfamily BAdolescentSubgroup analysisCohort StudiesYoung AdultInternal medicineGeneticsmedicineHumansAnthracyclinesChildAgedAged 80 and overPharmacologyGeneticsPolymorphism Geneticbusiness.industryStandard treatmentCytarabineInfantMyeloid leukemiaOdds ratioMiddle AgedConfidence intervalLeukemia Myeloid AcuteObservational Studies as TopicTreatment OutcomeChild PreschoolMeta-analysisCytarabineMolecular MedicineFemalebusinessmedicine.drugCohort studyThe Pharmacogenomics Journal
researchProduct

PML expression in soft tissue sarcoma: Prognostic and predictive value in alkylating agents/antracycline-based first line therapy

2012

Soft tissue sarcomas are aggressive tumors representing <1% of all adult neoplasms. Aim of our study was to evaluate promyelocytic leukemia gene expression value as prognostic factor and as a factor predicting response to alkylating agents/antracycline-based first line therapy. One hundred eleven patients affected by locally advanced and metastatic soft tissue sarcoma were selected. PML expression was evaluated by immunohistochemical analysis in pathological samples and in the corresponding normal tissue from each case. PML immunohistochemical results were correlated with prognosis and with radiological response to alkylating agents/antracycline-based first line therapy. PML expression was …

AdultMaleOncologymedicine.medical_specialtySettore MED/06 - Oncologia MedicaPhysiologyClinical BiochemistryCellDown-RegulationSoft Tissue NeoplasmsPromyelocytic Leukemia ProteinLiposarcomaPleomorphic LiposarcomaYoung AdultPredictive Value of TestsInternal medicinemedicineHumansAnthracyclinesAntineoplastic Agents AlkylatingPathologicalAgedRetrospective StudiesAged 80 and overPMLbusiness.industryTumor Suppressor ProteinsSoft tissue sarcomaNuclear ProteinsSoft tissueSarcomaCell BiologyMiddle AgedPrognosismedicine.diseaseImmunohistochemistrymedicine.anatomical_structuresoft tissue sarcomas; PMLDrug Resistance Neoplasmsoft tissue sarcomaImmunologyImmunohistochemistryFemaleSarcomabusinessTranscription Factors
researchProduct

Interdigital syphilis: a rare form of secondary syphilis

2019

A 39-year-old man with bilateral painful erosions in his toe web spaces and on the penile shaft was misdiagnosed as having Gram-negative toe web infection, and treated with broad-spectrum oral antibiotics. Further evaluation revealed positive serological tests for syphilis. Pedal interdigital syphilis is a rare manifestation of secondary syphilis.

AdultMalePenile Shaftmedicine.medical_specialtySexually Transmitted DiseasesDermatitisDermatologySecondary syphilisInjections IntramuscularFoot Diseases030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicinemedicineHumansPharmacology (medical)SyphilisTreponema pallidum030212 general & internal medicinebusiness.industryPublic Health Environmental and Occupational HealthSyphilis Cutaneousmedicine.diseaseDermatologyAnti-Bacterial Agentsbody regionsTreatment OutcomeInfectious DiseasesDoxycyclinePenicillin G BenzathineSyphilisbusinessInternational Journal of STD &amp; AIDS
researchProduct

Effect of non-surgical periodontal treatment with or without doxycycline on the periodontium of type 1 diabetic patients

2005

Aim: The present investigation was performed to study how type 1 diabetics responded to non-surgical periodontal treatment with and without adjunctive doxycycline. Method: Sixty diabetic type 1 patients (mean age 35.3 +/- 9 years) with moderate-to-severe periodontal disease were selected and divided into two groups of 30 patients each. Both groups were sex and age matched and had similar amounts of periodontal destruction. Plaque index (PI), bleeding on probing (BOP), probing depth (PD) and clinical attachment levels (CAL) were recorded. Group 1 (30 patients) was treated with oral hygiene instruction, scaling and root planing, chlorhexidine rinses twice a day and doxycycline (100 mg/day for…

AdultMaleTime Factorsroot planingBleeding on probingperiodontal diseaseDentistrylaw.inventionDiabetes ComplicationsScaling and root planingRandomized controlled triallawDiabetes mellitusmedicineHumansSingle-Blind MethodPeriodontal DiseasesDoxycyclinediabetesdoxycyclinebusiness.industryDental Plaque IndexChlorhexidinePeriodontiumMiddle Agedmedicine.diseaseDental Plaque IndexAnti-Bacterial AgentsDiabetes Mellitus Type 1Treatment OutcomeDental Care for Chronically IllDoxycyclineDental ScalingPeriodonticsFemaleperiodontal therapyPeriodontal Indexmedicine.symptombusinessmedicine.drugJournal of Clinical Periodontology
researchProduct

Treatment of human brucellosis with rifampin plus minocycline

2003

In order to evaluate the efficacy and tolerability of a high intravenous dose of rifampin plus oral minocycline (administered daily for 3 weeks) for the treatment of acute brucellosis, we retrospectively reviewed the outcome of 239 consecutive patients (135 adults and 104 children) diagnosed and treated over a 17-year period in Italy. The combination used resulted in 100% response and a relapse rate lower than 2%. Fifty-two (30 adults and 22 children) (29.8%) complained of mild adverse effects including an increase in aspartate aminotransferase (>250 IU) observed in 12 cases and considered related to rifampin and in 11 cases a reversible hyperpigmentation of the tongue attributed to minocyc…

AdultMalemedicine.medical_specialtyAdolescentmedicine.medical_treatmentMinocyclineRisk AssessmentDrug Administration SchedulePharmacotherapyRecurrenceInternal medicinemedicineHumansPharmacology (medical)ChildInfusions IntravenousAdverse effectAgedRetrospective StudiesAntibacterial agentAged 80 and overPharmacologyChemotherapyDose-Response Relationship Drugbusiness.industryRetrospective cohort studyMinocyclineMiddle AgedBrucellaSurgeryTreatment OutcomeInfectious DiseasesItalyOncologyTolerabilityChild PreschoolbrucellosisDrug Therapy CombinationFemaleRifampinbusinessRifampicinFollow-Up Studiesmedicine.drug
researchProduct